Document is current
Any future updates will be listed below
-
Authors
Zhang, Xiao
Fang, Hanyi
Yang, Biao
Qin, Chunxia
Hu, Fan
Ruan, Weiwei
Chen, Jing
Zeng, Dexing
Gai, Yongkang
Lan, Xiaoli https://orcid.org/0000-0002-7263-7399
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82372026, 81801738, 82030052)
Hubei Provincial Natural Science Foundation (2022CFB063)
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 24 November 2024
First Online: 29 November 2024
Declarations
:
: This study was approved by the institutional review board and registered at ClinicalTrials.gov (NCT06416774). All subjects gave written informed consent. All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: The corresponding author Xiaoli Lan is an editor in this journal. Dexing Zeng and Yongkang Gai hold the patent for the compound HX01. Dexing Zeng was employed by Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. All other authors declare that they have no conflict of interest.
